Abstract
Small-molecule docking remains one of the most valuable computational techniques for the structure prediction of protein-small-molecule complexes. It allows us to study the interactions between compounds and the protein receptors they target at atomic detail in a timely and efficient manner. Here, we present a new protocol in HADDOCK (High Ambiguity Driven DOCKing), our integrative modeling platform, which incorporates homology information for both receptor and compounds. It makes use of HADDOCK's unique ability to integrate information in the simulation to drive it toward conformations, which agree with the provided data. The focal point is the use of shape restraints derived from homologous compounds bound to the target receptors. We have developed two protocols: in the first, the shape is composed of dummy atom beads based on the position of the heavy atoms of the homologous template compound, whereas in the second, the shape is additionally annotated with pharmacophore data for some or all beads. For both protocols, ambiguous distance restraints are subsequently defined between those beads and the heavy atoms of the ligand to be docked. We have benchmarked the performance of these protocols with a fully unbound version of the widely used DUD-E (Database of Useful Decoys-Enhanced) dataset. In this unbound docking scenario, our template/shape-based docking protocol reaches an overall success rate of 81% when a reliable template can be identified (which was the case for 99 out of 102 complexes in the DUD-E dataset), which is close to the best results reported for bound docking on the DUD-E dataset.
Original language | English |
---|---|
Pages (from-to) | 4807-4818 |
Number of pages | 12 |
Journal | Journal of Chemical Information and Modeling |
Volume | 61 |
Issue number | 9 |
DOIs | |
Publication status | Published - 27 Sept 2021 |
Bibliographical note
Funding Information:We would like to acknowledge support from the European Union Horizon 2020 projects BioExcel (675728, 823830) and EOSC-hub (777536) and from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 101005077. The JU receives support from the European Union’s Horizon 2020 research and innovation program, EFPIA, Bill & Melinda Gates Foundation, Global Health Drug Discovery Institute, and University of Dundee.
Publisher Copyright:
© 2021 The Authors. Published by American Chemical Society.
Funding
We would like to acknowledge support from the European Union Horizon 2020 projects BioExcel (675728, 823830) and EOSC-hub (777536) and from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 101005077. The JU receives support from the European Union’s Horizon 2020 research and innovation program, EFPIA, Bill & Melinda Gates Foundation, Global Health Drug Discovery Institute, and University of Dundee.